drugset / Trial / NCT03033433
DCB-DM101 in Healthy Volunteers and for Type 2 Diabetes Mellitus Patients
NaSingle-groupOpen-labelTreatment
Summary
An Open-Label Phase I Study to Assess the Safety and Tolerability Profile of Three Escalating Doses of DCB-DM101 in Healthy Volunteers and Optimum Dose of DCB-DM101 as Add-on Treatment in Type 2 Diabetes Mellitus (T2DM) Patients
Timeline
- Start
- 2016-10
- Primary completion
- 2017-12
- Completion
- 2018-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DCB-DM101 | Unknown | 500 mg | Oral |
| Subject | DCB-DM101 | Unknown | 1000 mg | Oral |
| Subject | DCB-DM101 | Unknown | 2000 mg | Oral |